1984 CURE SMA WAS FOUNDED.

1995 We have grown to be the largest network of individuals, families, clinicians, and research partners working together to advance SMA research, support the SMA community, and educate public and professional communities about SMA.

2000 Discovery of backup gene as target for therapies.

2008 First study testing antisense therapy in SMA mice bysiRNA.

2009 Identification of SMN1 gene that causes SMA.

2010 First study testing gene therapy in SMA mice.

2011 First drug studied in SMA mice.

2014 First-ever clinical trial approved for an SMA-specific drug.

2016 FDA announcement approval of Spinraza to treat SMA, making it the first-ever FDA-approved therapy for SMA through Biogen.

2018 HHS Secretary Alex Azar approves adding SMA to the Recommended Uniform Screening Panel (RUSP), a major step towards implementing newborn screening nationwide.

2019 First-ever Orphan Drug Status awarded by the FDA for an SMA therapy.

2022 FDA announcement approval of Zolgensma for the treatment of children under the age of 2 years with SMA through Novartis.

2022 The Cure SMA Care Center Network comprises 18 hospital sites geographically dispersed throughout the U.S.

We have grown to be the largest network of individuals, families, clinicians, and research partners working together to advance SMA research, support the SMA community, and educate public and professional communities about SMA.

Approximately 97% of all babies born in the U.S. are now screened for SMA.